気管支炎治療の世界市場:2027年までに69億ドル規模へ

出版:BCC Research(BCCリサーチ) 出版年月:2022年11月

Bronchitis Treatments: Global Markets
気管支炎治療の世界市場:2027年までに69億ドル規模へ

ページ数 98
価格
 シングルユーザライセンス USD 5,500
 2-5ユーザライセンス USD 6,600
 サイトライセンス USD 7,920
 エンタープライズライセンス USD 9,504
種別 英文調査報告書

レポート目次  お問合せ・ご注文  価格・納期について

無料サンプル

BCC Research(BCCリサーチ)「気管支炎治療の世界市場:2027年までに69億ドル規模へ – Bronchitis Treatments: Global Markets」は世界の気管支炎治療市場を調査し、主要セグメント毎に行った分析・予測結果を提供します。

Report Highlights

The global market for bronchitis treatments is estimated to grow from $5.8 billion in 2022 to $6.9 billion in 2027, with a compound annual growth rate (CAGR) of 3.5% for the period of 2022-2027.

Summary:

The global market for bronchitis treatment was valued at $REDACTED billion in 2021. This market is estimated to grow with a compound annual growth rate (CAGR) of REDACTED% during the forecast period from 2022 to 2027. It is expected to be valued at $REDACTED billion in 2027.

Reasons for Doing This Study:

A growth in the prevalence of acute and chronic bronchitis has been observed, driven by the increasing global smoking population across and the rise in the geriatric population. Key players and stakeholders should understand market trends and be aware of currently available assays and the latest drug discovery developments.

Report Scope:

This study offers a global view of the treatment options for bronchitis in the market. This report analyzes and assesses the types of bronchitis, such as acute and chronic. It also provides information regarding different drugs classes, including antibiotics, anti-inflammatories and bronchodilators.

BCC Research analyzes and makes projections for each market and its segmentation, the regulatory environment, pipeline drugs and future aspects. The report also includes the impact of COVID-19 and profiles of leading companies in the bronchitis treatment market, including AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

The report covers the major markets of North America and Europe, as well as emerging markets, such as India, China, Japan and South Korea.

Report Includes:

– 35 total tables
– An overview of the global markets for the treatment options for bronchitis
– Analyses of the global market trends, with market revenue data and sales figures for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
– Highlights of the present and future strategies of the companies in the development of drugs and related treatment options for bronchitis, and areas of focus to forecast this market into various segments and sub-segments
– Estimation of the actual market size for bronchitis treatment, and corresponding market share analysis on the basis of disease type, drug class, treatment options, and geographic region
– Updated information on key market drivers and opportunities, industry shifts and regulations, and other demographic factors that will influence this market demand in the coming years (2022-2027)
– Insight into the patent grants and intellectual property aspects of the bronchitis treatment marketplace
– Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
– Descriptive company profiles of the leading pharmaceutical players, including AstraZeneca, Bayer AG, Cipla Inc., Sanofi and Pfizer Inc.


目次

Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of the Report
1.4 Methodology
1.5 Geographic Breakdown
1.6 Analyst’s Credentials
1.7 BCC Custom Research
1.8 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
3.1 Introduction
3.1.1 Disease Overview
3.1.2 Bronchitis Types
3.1.3 Pipeline Drugs
Chapter 4 Market Dynamics
4.1 Factors Affecting the Market for Bronchitis Treatments
4.2 Market Drivers
4.2.1 Increase in the Smokers
4.2.2 Growing Geriatric Population
4.2.3 Rise in Chronic Obstructive Pulmonary Disorder Patients
4.3 Market Restraints
4.3.1 Stringent Regulations
Chapter 5 Impact of COVID-19
5.1 COVID-19 Progression
5.2 Epidemiology
5.2.1 Collaboration Between Organizations and Governments
5.2.2 Spread of Disease
Chapter 6 Global Market for Bronchitis Treatments by Type
6.1 Global Market for Bronchitis Treatments by Type
6.2 Acute Bronchitis
6.3 Chronic Bronchitis
Chapter 7 Global Market for Bronchitis Treatments by Drug Class
7.1 Bronchodilators
7.2 Antibiotics
7.3 Anti-inflammatories
Chapter 8 Global Market for Bronchitis Treatments by Region
8.1 North America
8.1.1 U.S.
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 U.K.
8.2.2 Germany
8.2.3 France
8.2.4 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Rest of Asia-Pacific
8.4 South America
8.5 Middle East and Africa
Chapter 9 Company Profiles
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CIPLA INC.
DR. REDDY’S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

List of Tables
Summary Table A : Global Market for Bronchitis Treatments, Through 2027
Summary Table B : Global Market for Bronchitis Treatments, by Type, Through 2027
Summary Table C : Global Market for Bronchitis Treatments, by Drug Class, Through 2027
Table 1 : AstraZeneca Pipeline Drugs, 2022
Table 2 : COVID-19 Confirmed Cases and Deaths, by WHO Region, as of June 15, 2022
Table 3 : Global Market for Bronchitis Treatments, Through 2027
Table 4 : Global Market for Bronchitis Treatments, by Type, Through 2027
Table 5 : Global Market for Bronchitis Treatments, by Region, Through 2027
Table 6 : Global Market for Acute Bronchitis Treatments, Through 2027
Table 7 : Global Market for Chronic Bronchitis Treatments, Through 2027
Table 8 : Global Market for Bronchitis Treatments, by Drug Class, Through 2027
Table 9 : Global Market for Bronchodilators for Bronchitis Treatment, Through 2027
Table 10 : Global Market for Antibiotics for Bronchitis Treatment, by, Through 2027
Table 11 : Global Market for Anti-inflammatories for Bronchitis Treatment, Through 2027
Table 12 : Global Market for Bronchitis Treatments, by Region, Through 2027
Table 13 : North American Market for Bronchitis Treatments, by Country, Through 2027
Table 14 : European Market for Bronchitis Treatments, by Country, Through 2027
Table 15 : Asia-Pacific Market for Bronchitis Treatments, by Country, Through 2027
Table 16 : South American Market for Bronchitis Treatments, Through 2027
Table 17 : Middle East and African Market for Bronchitis Treatments, Through 2027
Table 18 : AstraZeneca: Financial Performance, 2018-2021
Table 19 : Bayer AG: Marketed Products
Table 20 : Bayer AG: Net Revenue, 2016-2021
Table 21 : Cipla’s Key Financials 2021 and 2022
Table 22 : Dr. Reddy’s Key Financials 2021
Table 23 : GlaxoSmithKline: Product Segment
Table 24 : GlaxoSmithKline: Key Financials 2021
Table 25 : GlaxoSmithKline plc: Recent Developments
Table 26 : Merck & Co. Inc.: Business Segment
Table 27 : Merck & Co. Inc.: Financial Performance, 2018-2021
Table 28 : Novartis Key Financials, 2021
Table 29 : Novartis AG: Key Developments
Table 30 : Pfizer: Business Segment
Table 31 : Pfizer Inc. Revenue, 2021
Table 32 : Sanofi: Business Segment
Table 33 : Sanofi: Financial Performance, 2021
Table 34 : Sun Pharmaceutical: Key Financials 2021
Table 35 : Teva Pharmaceutical Industries Key Financials 2021

List of Figures
Summary Figure A : Global Market for Bronchitis Treatments, 2020-2027
Summary Figure B : Global Market for Bronchitis Treatments, by Type, 2020-2027
Summary Figure C : Global Market for Bronchitis Treatments, by Drug Class, 2020-2027
Figure 1 : Global Market for Bronchitis Treatments, by Type, 2020-2027
Figure 2 : Global Market Shares of Bronchitis Treatments, by Type, 2021
Figure 3 : Global Market for Bronchitis Treatments, by Region, 2020–2027
Figure 4 : Global Market for Treatments for Acute Bronchitis, 2020-2027
Figure 5 : Global Market for Chronic Bronchitis Treatments, 2020-2027
Figure 6 : Global Market for Bronchitis Treatments, by Drug Class, 2020-2027
Figure 7 : Global Market for Bronchitis Treatments, by Drug Class, 2021
Figure 8 : Global Market for Bronchodilators for Bronchitis Treatment, 2020-2027
Figure 9 : Global Market for Antibiotics for Bronchitis Treatment, 2020-2027
Figure 10 : Global Market for Anti-inflammatories for Bronchitis Treatment, 2020-2027
Figure 11 : Global Market for Bronchitis Treatments, by Region, 2020-2027
Figure 12 : Global Market Shares of Bronchitis Treatments, by Region, 2021
Figure 13 : North American Market for Bronchitis Treatments, by Country 2020–2027
Figure 14 : U.S. Market for Bronchitis Treatments, 2020-2027
Figure 15 : Canadian Market for Bronchitis Treatments, 2020-2027
Figure 16 : Mexican Market for Bronchitis Treatments, 2020-2027
Figure 17 : European Market for Bronchitis Treatments, by Country, 2020-2027
Figure 18 : U.K. Market for Bronchitis Treatments, 2020-2027
Figure 19 : German Market for Bronchitis Treatments, 2020-2027
Figure 20 : French Market for Bronchitis Treatments, 2020-2027
Figure 21 : Rest of the European Market for Bronchitis Treatments, 2020-2027
Figure 22 : Asia-Pacific Market for Bronchitis Treatments, by Country, 2020-2027
Figure 23 : Chinese Market for Bronchitis Treatments, 2020-2027
Figure 24 : Japanese Market for Bronchitis Treatments, 2020-2027
Figure 25 : Indian Market for Bronchitis Treatments, 2020-2027
Figure 26 : South Korean Market for Bronchitis Treatments, 2020-2027
Figure 27 : Rest of APAC Market for Bronchitis Treatments, 2020-2027
Figure 28 : South American Market for Bronchitis Treatments, 2020-2027
Figure 29 : Middle East and African Market for Bronchitis Treatments, 2020-2027
Figure 30 : AstraZeneca: Sales Share, by Segment, 2021
Figure 31 : AstraZeneca: Revenue Share, by Region, 2021
Figure 32 : Bayer AG: Revenue Share, by Region, 2021
Figure 33 : Bayer AG: Revenue Share, by Business Segment, 2021
Figure 34 : Boehringer Ingelheim: Annual Revenue, 2021
Figure 35 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
Figure 36 : Boehringer Ingelheim: Revenue Share, by Region, 2021
Figure 37 : Dr. Reddy’s: Revenue Share, by Business Segment, 2021
Figure 38 : GlaxoSmithKline plc: Net Revenue, 2016-2020
Figure 39 : GlaxoSmithKline plc: Revenue Share, by Business Segment, 2021
Figure 40 : GlaxoSmithKline plc: Revenue Share, by Region, 2021
Figure 41 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 42 : Merck & Co. Inc.: Revenue Share, by Region, 2021
Figure 43 : Novartis: Revenue Share, by Business Segment, 2021
Figure 44 : Novartis: Total Revenue Share, by Region, 2021
Figure 45 : Pfizer Inc.: Revenue Share, by Region, 2021
Figure 46 : Pfizer Inc.: Revenue Share, by Business Segment, 2021
Figure 47 : Sanofi: Net Sales Share, by Business Segment, 2021
Figure 48 : Sanofi: Net Sales Share, by Region, 2021
Figure 49 : Sun Pharmaceutical: Revenue Share, by Business Segment, 2021
Figure 50 : Sun Pharmaceutical: Total Revenue Share, by Region, 2021
Figure 51 : Teva: Annual Revenue, 2018-2020
Figure 52 : Teva Pharmaceutical Industries: Revenue Share, by Business Segment, 2021
Figure 53 : Teva Pharmaceutical Industries: Total Revenue Share, by Region, 2021


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com